Prazobind

Prazobind (SZL 49), a prazosin analog, is an irreversible α1-adrenoceptor antagonist. Prazobind competes for alpha 1-adrenoceptor binding sites with a similar potency (IC50 of 1 nM) in tissues enriched in both the alpha 1A (hippocampus) and alpha 1B (liver) subtypes. Prazobind partially inhibits the contractions of circular muscles, longitudinal muscles and smooth muscles of the spleen. Prazobind can be used for the study of blood pressure[1][2][3][4].

Product Specifications

CAS Number

[107021-36-3]

Product Name Alternative

SZL 49

UNSPSC

12352005

Target

Adrenergic Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/prazobind.html

Purity

96.20

Solubility

DMSO : 0.1 mg/mL (ultrasonic; warming)

Smiles

NC1=NC(N(CC2)CCN2C(C3=CC4CCC3C=C4)=O)=NC(C=C5OC)=C1C=C5OC

Molecular Formula

C23H27N5O3

Molecular Weight

421.49

References & Citations

[1]Mante S, et al. The alkylating prazosin analog SZL 49 inactivates both alpha 1A- and alpha 1B-adrenoceptors. Eur J Pharmacol. 1991;208 (2) :113-117. |[2]Tabrizchi R, et al. The effects of losartan and captopril on vasopressor actions of cirazoline in the absence and presence of SZL-49 and nifedipine. J Cardiovasc Pharmacol. 1995 Jul;26 (1) :137-44.|[3]Amobi NI, et al. Discrimination by SZL49 between contractions evoked by noradrenaline in longitudinal and circular muscle of human vas deferens. Br J Pharmacol. 2002 May;136 (1) :127-35.|[4]Eltze M. Functional evidence for an alpha 1B-adrenoceptor mediating contraction of the mouse spleen. Eur J Pharmacol. 1996 Sep 12;311 (2-3) :187-98.